Getting Any Better

Quote
For all you CP Gordon Geckos, let's keep things in perspective.

Based on today's call, the company missed domestic sales by a system or two. Cash burn is at expected/forecasted levels. EC will have $43-$45 million at the end of 2016 with another $15 million credit line. Gen 3 delayed a few deals so they would have hit their number but a few customers asked to re-demo with the new stuff. Other areas of the business are heathy and growing. Profitability has always been forecasted to be 2-3 years away and based on current sales & cash burn is still on track. Lumos was an unexpected early approval as were these air water valves. Several Hedge funds recently increased their holdings. All true, all easily verified facts.
 












anonymous said:
For all you CP Gordon Geckos, let's keep things in perspective.

Based on today's call, the company missed domestic sales by a system or two. Cash burn is at expected/forecasted levels. EC will have $43-$45 million at the end of 2016 with another $15 million credit line. Gen 3 delayed a few deals so they would have hit their number but a few customers asked to re-demo with the new stuff. Other areas of the business are heathy and growing. Profitability has always been forecasted to be 2-3 years away and based on current sales & cash burn is still on track. Lumos was an unexpected early approval as were these air water valves. Several Hedge funds recently increased their holdings. All true, all easily verified facts.
Click to expand...

Not sure if I would call the other areas of the business "healthy" when they are growing at less 10% and the company's revenue was only up 3.3% vs. prior year. I would expect to see the units of Fuse pick up after being out for 2.5 years but we are still seeing low teens for the US market.

I'll give MG credit, he is great at selling snake oil. Last year, he was selling the benefits of GEN2 and the tenured sales force while blaming the summer vacations as to why the deals are so few. This year, it is because customers are waiting until GEN3.

Unless this company starts dropping 200 Fuse units a year, they won't ever be profitable. Fuse is the anchor around its neck and disposable buttons/single use products and pathology will never take enough market share to make up for the quarterly loses. The disposable products and pathology markets are completely commoditized with several other vendors offering the exact same options for customers.
 












anonymous said:
For all you CP Gordon Geckos, let's keep things in perspective.

Based on today's call, the company missed domestic sales by a system or two. Cash burn is at expected/forecasted levels. EC will have $43-$45 million at the end of 2016 with another $15 million credit line. Gen 3 delayed a few deals so they would have hit their number but a few customers asked to re-demo with the new stuff. Other areas of the business are heathy and growing. Profitability has always been forecasted to be 2-3 years away and based on current sales & cash burn is still on track. Lumos was an unexpected early approval as were these air water valves. Several Hedge funds recently increased their holdings. All true, all easily verified facts.
Click to expand...

Let's keep something else in perspective. EC purchased FUSE at waaaaaaay too high of a price. That product isn't only not selling well; it's selling pathetically. Investment continues to be swindled that the tracking will come. It won't. Profitability was forecasted two years ago for now and that isn't happening. Stock is at an all-time low. When EC first went public last June 1st, the initial price was $17.00 a share. It's currently trading at $4.00. HOW can VC's still be giving money to this POS organization? College courses will use EC as an example of how not to compete in today's medical device world.
 






anonymous said:
For all you CP Gordon Geckos, let's keep things in perspective.

Based on today's call, the company missed domestic sales by a system or two. Cash burn is at expected/forecasted levels. EC will have $43-$45 million at the end of 2016 with another $15 million credit line. Gen 3 delayed a few deals so they would have hit their number but a few customers asked to re-demo with the new stuff. Other areas of the business are heathy and growing. Profitability has always been forecasted to be 2-3 years away and based on current sales & cash burn is still on track. Lumos was an unexpected early approval as were these air water valves. Several Hedge funds recently increased their holdings. All true, all easily verified facts.
Click to expand...
 






anonymous said:
For all you CP Gordon Geckos, let's keep things in perspective.

Based on today's call, the company missed domestic sales by a system or two. Cash burn is at expected/forecasted levels. EC will have $43-$45 million at the end of 2016 with another $15 million credit line. Gen 3 delayed a few deals so they would have hit their number but a few customers asked to re-demo with the new stuff. Other areas of the business are heathy and growing. Profitability has always been forecasted to be 2-3 years away and based on current sales & cash burn is still on track. Lumos was an unexpected early approval as were these air water valves. Several Hedge funds recently increased their holdings. All true, all easily verified facts.
Click to expand...


An amazing job at turd shining
 
















































Yes. It is on the website. They sold approximately 6 million shares at $5.1 per share. Smart to do it before the earnings call and make an extra dollar per share before the earnings report goes out.
 






anonymous said:
Let's keep something else in perspective. EC purchased FUSE at waaaaaaay too high of a price. That product isn't only not selling well; it's selling pathetically. Investment continues to be swindled that the tracking will come. It won't. Profitability was forecasted two years ago for now and that isn't happening. Stock is at an all-time low. When EC first went public last June 1st, the initial price was $17.00 a share. It's currently trading at $4.00. HOW can VC's still be giving money to this POS organization? College courses will use EC as an example of how not to compete in today's medical device world.
Click to expand...

Dick
 






anonymous said:
Yes. It is on the website. They sold approximately 6 million shares at $5.1 per share. Smart to do it before the earnings call and make an extra dollar per share before the earnings report goes out.
Click to expand...

Hard to fathom that there are people stupid enough to buy this stock in a secondary offering. Well, as the saying goes, a fool and his money soon part.
 












anonymous said:
Yes. It is on the website. They sold approximately 6 million shares at $5.1 per share. Smart to do it before the earnings call and make an extra dollar per share before the earnings report goes out.
Click to expand...

Again..Gordon Gecko, read the actual press release. This is simply a registration in case the company needs to raise money. A precautionary, smart move that was discussed on the earnings call. Company is forecasting $43-45 million in cash plus another $15 in credit line at the END of 2016. This funds the company through 2017 & into 2018. The shelf registration is a filing that allows them to sell shares IF they want/need to raise more money. See below for further explanation.

Shelf registration is a procedure, included in a regulation, that a corporation can evoke to comply with U.S. Securities and Exchange Commission (SEC) registration requirements for a new stock offering up to two years before doing the actual public offering.
 






anonymous said:
For all you CP Gordon Geckos, let's keep things in perspective.

Based on today's call, the company missed domestic sales by a system or two. Cash burn is at expected/forecasted levels. EC will have $43-$45 million at the end of 2016 with another $15 million credit line. Gen 3 delayed a few deals so they would have hit their number but a few customers asked to re-demo with the new stuff. Other areas of the business are heathy and growing. Profitability has always been forecasted to be 2-3 years away and based on current sales & cash burn is still on track. Lumos was an unexpected early approval as were these air water valves. Several Hedge funds recently increased their holdings. All true, all easily verified facts.
Click to expand...

You're going to mention Lumos? Do you work here? If you've ever worked here, you would know that all Lumos is, is a fix to our otherwise less than stellar image that we have with our system. My guess is that the image issues are either due to the fact that we don't have an HD image from the Fusebox to the Fusepanel or it is the multiple connections from the Fusebox to the curved?

Plus, the one thing that anyone knows(if you work here), is that the driveability of our scope SUCKS. Then, let's sell a coat hanger wire that we can shove down the working channel instead of working on variable stiffness. Unless GEN3 fixes it considerably, the "enhanced" image won't do that much..

Don't get me started on the earnings report that mentioned that we've cut back on our R&D to cut operating expenses. Unless we get a full line of scopes soon, we aren't going to consistently score multiple room deals in medium to large hospitals.
 






Top Bottom
Back
Quote